TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00321100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
Study: NCT02192359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carboxylesterase-expressing Allogeneic Neural Stem Cells
Description: Given intracranially

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT04813055

Intervention type: PROCEDURE
Intervention: Therapeutic EUS
Description: 1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage

Intervention type: PROCEDURE
Intervention: Percutaneous Procedures
Description: Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)

Intervention type: PROCEDURE
Intervention: Surgical Interventions
Description: Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)

Intervention type: PROCEDURE
Intervention: non-EUS-based endoscopic procedures
Description: Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
Study: NCT02898038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES PARIS
Description: AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study: NCT02192359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01716702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Prostate Cancer Support Group
Description: The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).
Study: NCT04211883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE intervention
Description: The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
Study: NCT00536185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
Study: NCT05091359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste
Description: Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
Study: NCT03006107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraligamentary injection piroxicam
Description: intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraligamentary mepevacaine
Description: mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
Study: NCT02845934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
Study: NCT02888340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
Study: NCT02685410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Night Stan Prototype
Description: The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
Study: NCT01869517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrastromal corneal ring segments (Keraring) implantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal continuous ring (Myoring) implantation
Study: NCT04253262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib (PO twice daily continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)
Study: NCT00321100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 IV day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
Study: NCT04253262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)
Study: NCT03556774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'WeChat WeQuit' smoking cessation training program
Description: Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
Study: NCT00453063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: 50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sprays in each nostril once daily in the morning
Study: NCT01805921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intra-nasally (high dose)
Description: High dose = 5x10\^10 vp
Study: NCT01586065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: CGM during 24-hr CRC stay.
Study: NCT00114530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mHSCT
Description: Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
Study: NCT01805921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu
Study: NCT00114530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
Study: NCT03949036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid fluid administration with the target of stroke volume variation ≤ 12%
Description: The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid fluid administration with the target of stroke volume variation ≤ 6%
Description: The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
Study: NCT03572972

Intervention type: DRUG
Intervention: Apixaban
Description: Treatment for NVAF patients
Study: NCT06565299

Intervention type: PROCEDURE
Intervention: Cardiovascular surgery with cardiopulmonary bypass
Description: Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
Study: NCT01805921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (high dose)
Description: High dose = 1x10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (high dose)
Description: High dose = 5x10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intranasally (low dose)
Description: Low dose = 5x10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given intranasally (low dose)
Description: Low dose = 5x10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (low dose)
Description: Low dose = 1x10\^7 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-RSV given by intra-muscular injection (low dose)
Description: Low dose = 1x10\^7 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (low dose)
Description: Low dose = 5x10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (low dose)
Description: Low dose = 5x10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PanAd3-RSV given by intra-muscular injection (low dose)
Description: Low dose = 5x10\^9 vp
Study: NCT03860220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEWSTATIN TS
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
Study: NCT00689884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
Study: NCT04035031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
Study: NCT01221116

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: levosimendan
Description: levosimendan 0.1 microgram/kg/min) for 24 hours
Study: NCT04013178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric loading + electromyostimulation
Description: An innovative training intervention to optimize muscle strength and muscle mass

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resistance training
Description: A conventional approach to resistance training
Study: NCT02076711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprololsuccinate
Study: NCT03860220

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CADUET
Description: Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
Study: NCT03342651

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin D
Description: Vitamin D, general anesthesia, respiratory complications
Study: NCT02061332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 Pulsed Dendritic cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 Pulsed Dendritic cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 Pulsed Dendritic cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
Study: NCT00907218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline (Chantix)
Description: Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
Study: NCT04073914

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type 1 Teamwork Program
Description: Psychoeducational web program
Study: NCT02347163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
Study: NCT00627874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +3D Lenses
Description: wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
Study: NCT00696618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fleet Enema
Description: hyper-osmolar preparation
Study: NCT01790737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Study: NCT03726671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study: NCT02076711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04717401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain
Description: Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
Study: NCT03199313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.
Study: NCT00696618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fleet Enema
Description: hyper-osmolar preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fleet Enema
Description: hyper-osmolar preparation
Study: NCT03199313

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo